
Index

A

acinar, 70, 72, 114–117, 178, 218, 221, 225–231, 234–235, 259–260, 263, 274–277
cell carcinoma, 70, 72, 218, 228
activin, 275
adenocarcinoma, 1–3, 7, 68–70, 72, 74, 91, 103–104, 110, 116, 175, 176, 178, 185–187, 221, 224, 228–229, 231, 259–260, 273–274, 299, 305–306, 308
adenoma, 1, 3–8, 199–201
adenovirus (*see* viral/virus)
Affymetrix, 131, 133, 175–177, 181–186
allele/allelic, 137–140, 143, 151, 221, 232, 234, 250–251, 253–254, 332–334, 336–337
imbalance, 137, 140
loss, 143
allogeneic, 299–300, 306, 308–309, 312
amylase, 70, 115, 229, 277
anchoring enzyme, 162, 164, 167
animal model (*also see* carcinogen, hamster, gene-targeted, mouse, rats, transgenic, and zebrafish), 114, 217–218, 220, 224, 228, 234–236, 276, 303
antibody/antibodies, 10, 34, 37, 43, 45, 58–60, 75, 77–79, 83, 90, 99, 116, 126, 128, 130–131, 177, 207–210, 213, 215, 222, 267–268, 277–278, 281, 283, 286, 292, 300–304, 319
antigen/antigenic, 10, 59, 68, 77, 116–117, 130, 207–208, 215, 228, 281, 286, 292, 299–309, 312, 318, 320
retrieval 59, 77–78, 130
antigen presenting cells (APC), 307–308

antisense (*also see* morpholinos and RNA), 281–282, 284, 288–289
APC, 70, 72–73, 235,
5-aza-2'-deoxycytidine (5-aza-dC), 123–125, 127–129, 133–134

B

bacteria, 17, 128, 131, 171, 209, 211, 213–214, 248, 304
basic helix-loop-helix (bHLH), 275
B-cells, 209, 215, 300–304
 β -catenin, 70, 72–74, 228, 235
 β -galactosidase, 231–232, 317
bioinformatics, 191, 194
biomarker 59, 89, 189–191, 195, 309
biotin, 10, 37, 45, 75–79, 82–83, 128, 134, 146, 162, 164, 166, 172, 177, 180
bisulfite modification, 123–124, 126–127, 130–131
BLAST search, 276, 320
blood, 16, 19, 43, 59–60, 68, 74, 109, 114, 264, 319, 331
bombesin, 115,
bovine pituitary extract, 115, 118
BRCA2, 144, 150, 305, 329–330, 334, 340
BrdU (5-bromo-2'-deoxyuridine), 281, 284, 290–291

C

cancer vaccine (*see* vaccine)
carbachol, 115
carbohydrate antigen (CA), 68, 72
carboxypeptidase A, 278–280

- carcinoembryonic antigen (CEA), 68, 72, 222, 303, 306
- carcinogen/carcinogenic, 40, 57, 113, 217–221, 224, 228–232, 235, 260, 292
- carcinoma *in situ*, 2, 4–6, 8, 229–230
- caudal–rostral axis, 265
- cDNA, 18, 60, 63, 80, 117, 119, 113, 144, 158, 161–162, 164, 166–168, 172–173, 176, 179–180, 207–210, 214–215, 311
- cell
- aggregation, 269
 - concentration, 20, 34, 42
 - culture, 97, 114–116, 128, 133–134, 166, 173, 178, 210, 221
 - differentiation (*see* differentiation)
 - enrichment, 50
 - fixed, 92, 97
 - frozen, 125, 118, 315, 316, 318
 - line, 91–92, 97, 103–104, 106, 109, 114, 117, 125, 129, 151, 175–176, 178, 186–187, 190, 203, 208, 210, 214–215, 219–220, 223, 260, 274, 308, 311–319
 - lysis, 34, 43
 - microdissection (*see* microdissection)
 - proliferation, 114
 - purification, 16
 - separation, 33, 59, 114
 - transplant, 217–223, 235
 - types, 15–16, 20–21, 114, 117, 221, 224–225, 231, 234, 260
 - xenograft (*see* xenograft)
- cellular/cellularity, 20, 25, 27, 29, 41, 59, 103, 115, 117, 143–144, 178, 190, 217–218, 220–221, 224–225, 235, 259, 282, 292, 300–301, 304–305, 308
- chimera/chimeric, 232–233
- cholera toxin, 115–116
- chronic pancreatitis (*also see* pancreatitis), 260
- chymotrypsin, 70, 115
- clinical, 1, 3, 67, 70, 74, 90, 92, 137, 273–274, 282, 299–300, 303–310, 318–320
- collagen, 114–116 260–264
- collagenase, 33, 42, 115, 119, 261, 262
- combined bisulfite restriction analysis (COBRA), 124–126, 128
- CpG island, 123–127, 129–132, 134, 144
- CrelloxP*, 227, 231–232, 234, 245–249, 251, 253–254, 256
- cryostat sectioning (*see* tissue sectioning)
- cystic fibrosis transmembrane conductance regulator (CFTR), 115
- cytokeratin, 68, 72, 75, 114–116, 119, 225, 227
- cytokeratin 19 (*CK19*), 114–116, 119, 225, 227–229, 231
- cytokine, 33, 299–300, 304, 307, 309–310, 314, 318–320
- cytologic/cytology, 3–7, 21, 33, 58–59, 62, 202–203
- D**
- DAB (3',3-diaminobenzidine), 37, 45, 60, 75–76, 78–79, 82–83, 215
- delayed-type hypersensitivity (DTH), 306–308
- dendritic cells, 301, 304–305, 307–308
- deparaffination, 78
- development (*see* pancreatic development or tumor development)
- dexamethasone, 115, 261–262, 269
- diagnosis/diagnostic, 1, 4, 6, 19, 67–68, 91, 93–94, 97, 123–124, 133, 189, 191, 199–201, 218, 273, 303
- differentiation, 68, 70, 72, 74–75, 114–116, 126, 143, 208, 223, 231, 259–260, 274–277, 279–280, 305, 307
- digital, 137–140

DNA

amplification, 7, 63, 79, 82, 127, 132, 134, 137, 127, 147–149, 154, 157, 169, 172, 203

collection, 331, 338

denature, 130, 291

digestion (dsDNA), 39, 61, 127, 129, 131–133, 144, 153, 155, 167–168, 170

electroporation, 309

extraction, 7–9, 39, 53, 153–154, 156–157, 167, 168–171, 214, 289

isolation, 19, 38–39, 37, 52–53, 57, 103, 126, 151

ligation, 165, 167–169, 171, 173, 179, 214

methylation (*also see* methylation), 126–127, 129, 131–132, 134, 221

microinjection, 224, 309

probe, 79–80

proviral, 311

purification, 40, 127, 130, 134, 138, 140

quality, 39, 57, 134, 137–138, 166, 173

quantity, 20, 28, 35, 39, 47, 60, 126, 140, 151, 157, 171, 214

sequencing (*also see* sequencing), 162, 164–165, 172–173, 209

transfection, 309

DNase, 41, 56, 283, 289

dorsal, 265, 267, 269, 275

DPC4 (*also see SMAD4*), 9–10, 68–70, 72, 74, 305

ductal, 1–7, 68, 70, 72, 74, 104, 113–119, 203, 218, 221, 223–226, 228–231, 259–260, 273–274, 306

ductal epithelial cells (DEC), 113–117

E

E-cadherin, 123–124, 222

elastase (*EL*), 224–230, 234

electrophoresis, 41, 133, 149, 156, 164, 166, 173, 189–190, 193, 203, 247, 289

embryo/embryonic, 124, 224, 232–233, 245, 259–261, 264–265, 267, 276–277, 279–282, 284–287, 289–293, 301–303,

embryonic stem cell (ES cell), 227, 232–233, 245–247, 249–250, 254, 256, 289–293

endocrine

cell /lineage, 68, 114, 116–117, 231, 259, 274–277, 279

hormone, 281

neoplasm, 72, 74–75

endoplasmic reticulum (ER), 19, 301–303

endoscopic retrograde pancreatography (ERP), 200–201, 203

enzyme-linked immunosorbent assay (ELISA), 318

epidermal growth factor (EGF), 115, 118, 276

epithelial/epithelium, 3–7, 9, 33, 50, 68, 72, 90, 115–119, 175–176, 178, 186, 200–202, 208, 225, 229–231, 259–260, 262–265, 267–269, 275, 277, 279, 301, 306

(epithelial aggregate separation and isolation (EASI), 7, 9, 50–51, 59, 62

epithelial membrane antigen (EMA), 68, 72

Epstein-Barr virus (*see* viral/virus)

exocrine, 68, 72, 114, 217, 220, 224, 228, 231, 262–263, 274–281

explant, 114–117, 259–261, 263–265, 267

F

familial, 260, 329–330

fibroblast, 114–117, 311, 314

fibroblast growth factor-2 (FGF-2), 275
 Ficoll, 34, 43, 59, 115–116,
 fine-needle microdissection, 7
 fluorescence/fluorescent, 19, 24–25, 89,
 140, 185, 264, 283, 286–288,
 292
 follistatin, 275
 formalin-fixed (*also see* tissue), 7, 9,
 18, 35–36, 41, 43, 56–59, 62,
 77, 79, 92, 97, 109, 128, 130
 frozen (*also see* tissue), 9, 16, 18, 20,
 33–36, 39, 41, 44–45, 47, 53,
 58–63, 77, 125, 176, 178–179,
 187, 210, 214
frt/flp, 231, 235, 246–247, 250–251,
 253–254

G

γ -glutamyl transferase, 115
 glycosyl transferase, 306
 gene/genetic
 activation, 310
 alteration (*also see* mutation), 1–4,
 144–145, 220, 229, 231, 234,
 259
 chip, 175–176, 183–185
 cloning, 150, 207, 209, 311
 disease-causing, 330–331, 334,
 337–339
 expression, 79–80, 123–124, 127, 129,
 133–134, 161–162, 175–176, 178,
 186–187, 189, 217, 224–225,
 227–232, 235, 245, 274–275, 306,
 309, 310, 315–316, 318–320
 heterogeneity, 232, 267, 334–335,
 339
 identification 144, 150, 176, 178,
 209, 229, 282,
 inactivation, 68, 123–124
 knockdown, 277, 281–282
 knock-out (*also see* knockout mice),
 232, 245, 250, 253
 linkage (*see* linkage)
 marker (*also see* biomarker,
 microsatellite, molecular
 marker), 199–200, 232, 317,
 330, 332–339
 mutation (*also see* gene alteration and
 mutation), 74, 200, 217–218,
 219, 233–234
 regulation, 224, 225–226, 228, 231,
 245, 274–276
 sequencing (*see* sequencing)
 silencing, 123–124
 targeting (*also see* gene-targeted),
 217, 232, 234, 245–247, 250,
 253, 255–256, 275–276, 281
 therapy (*also see* immunotherapy),
 318
 transfer, 309–314, 316, 318–320
 translation, 190, 281
 GeneChip Array, 133, 182–184, 219,
 232, 234
 gene-targeted (*also see* RMDI and
 RMCE), 217, 219, 232, 234,
 245–247, 250, 253, 255–256
 genome, 94, 123–125, 127, 129, 133,
 138, 143–148, 150–152, 157,
 161–162, 181, 276, 300, 309–
 311, 316
 candidate region, 123–124, 127, 143,
 337
 fine mapping, 138, 337–338
 gene-targeting (*see* gene-targeted
 and gene targeting)
 scanning (*also see* RLGS), 124, 127,
 129, 132–134, 177, 181, 183–185,
 337–339
 genotype/genotyping, 15–16, 331–332,
 338
 granulocyte-macrophage colony-
 stimulating factor (GM-CSF),
 300, 307–309, 319
 green fluorescent protein (GFP), 220,
 263, 269
 growth factor, 33, 115, 118, 218, 225,
 228, 235, 260, 263–264, 269,

274–276, 302, 318

H

hairy/Enhancer of split 1 (Hes1), 275

hamster, 114, 217, 220–224

Hedgehog signaling, 275

hematopoietic/hematopoiesis, 276, 301

H&E (hematoxylin and eosin) staining,

19–20, 44, 47, 51, 58, 60–61,

67, 69–70, 73, 75–76, 78–79,

82, 89, 94–95, 178, 187

hepatocyte growth factor, 115

HER-2/neu, 218, 302–303, 305

hereditary nonpolyposis colorectal carcinoma (HNPCC), 70

heterozygous/heterozygosity, 144, 151,

232, 234, 332, 337

HLA, 301, 306, 308, 320

hIxb9, 275

hnf1 α , 275

HPLC (high performance liquid chromatography), 124–126,

128, 134, 152, 176–177

H-ras, 305

histology, 35–36, 41, 57–59, 70, 74,

277, 283, 287

homozygous deletion, 143–144, 150–152

hormone, 75, 115, 225, 275, 277–279, 281

hTERT, 117, 119, 200

human papillomavirus (HPV)

(*see viral/virus*)

hydrocortisone, 115

I

identical by decent (IBD), 336–337

inducible transgene, 226, 231, 234

informative, 140, 331–332

inherited, 70, 332–333, 336

in situ hybridization, 67–68, 70, 76, 79–83,

89–90, 279–281, 283, 288–289

insulin, 33, 75, 115, 117, 277–281

insulin-like growth factor-1, 115

interleukin (IL), 115, 304, 319

image analysis, 22, 24, 28, 32, 48,
69, 90, 92–94, 138, 183–185,
194, 204, 269, 273

immortalization, 113, 117, 119,
199–200, 259–260

immunization, 299–301, 306–307

immunodeficient, 103, 217–220

immunohistochemical (IHC)

labeling/

immunohistochemistry, 9–10,

16, 20, 42, 45, 59–60, 67–68,

70, 72–77, 82–83, 89, 94,

97–98, 123, 124–126, 128,

130, 209, 264, 267–268, 277,

279–281, 286–287, 291–292

immunoscreening, 207, 212

immunotherapy, 230, 300, 303–304

imprinting, 124

interleukin-6 (IL-6), 319

IPMN (intraductal papillary mucinous neoplasm), 2–6, 9–10, 72

intraepithelial, 1–2, 4–5, 68, 91, 260

invasive, 2–7, 10, 68–69, 74, 91, 200,

221, 229, 231, 260, 274

isl-1, 275, 277

islet cell, 68, 114–117, 221, 228, 231,

259–260, 263, 274–275, 277–281

K

K-ras, 68, 200, 234, 303, 305

Ki-67, 74–75

kinetic enrichment, 126, 143, 146–147,
149, 158

knockout mice, 218, 227–229, 232,

234, 245, 249–251, 253

conditional, 234–235, 245, 249–251

L

lacZ, 317

laminin-1/nidogen matrix, 116, 275

LCM (laser capture microdissection)

(*also see* microdissection), 7–9,

21, 23, 25, 28–29, 38–40, 45,
48–52, 54, 58–60, 62–63
linkage/linkage analysis, 144, 329–340
lipase, 70, 72, 74, 277
LOD score, 333–335, 339
long terminal repeat (LTR), 311

M

macrophage, 222, 300–301, 305, 308
magnetic-bead separation, 34, 43
mass spectrometry, 189–190, 193, 196
Matrigel, 104, 109, 114, 116
medullary carcinoma, 68–70
Mendelian disease, 329, 333
mesenchymal, 219, 260, 268, 275–276
 neoplasm, 68, 75
metaplasia, 2, 228–229, 231, 234, 259–260,
 274
metastasis/metastatic, 110, 218–220,
 222–223, 229, 273, 306, 312
methylation (*also see* DNA methylation),
 123–134, 144, 221
MHC, 302–303, 305, 319
microarray
 DNA 144, 189
 oligonucleotide, 129, 131–133, 175–187
 methylation-specific oligonucleotide
 (MSO), 124–126, 129, 131–133
 tissue (*also see* tissue), 89–100
microdissection (*also see* fine-needle
 microdissection, LCM), 7–10,
 15–16, 18–22, 28–33, 35–38,
 40, 42–51, 55, 59–63, 126,
 138, 151, 178–179, 187, 261
microenvironment, 304
microinjection, 281, 284, 290–291,
 293, 309,
microsatellite, 68, 70, 137–138, 145,
 332, 338
microscope/microscopic, 3–4, 8–10,
 20–22, 28, 30, 33–34, 37–38,
 47–51, 57–59, 61, 70, 72,
 79–81, 83, 89, 93, 114, 263,

283, 285, 287, 288, 290–292
mismatch repair gene, 70
mitogen, 115
MLH1, 70
molecular
 beacon, 138–140
 marker, 279
 profiling/analysis, 7, 16–63, 137–138,
 161, 274, 276, 281
Moloney murine leukemia virus
 (Mo-MuLV) (*see* viral/virus)
morpholinos, 277, 281–282, 284, 292–293
mouse/mice, 79, 103–111, 184, 220–224,
 229–235, 245, 247, 256, 259–265,
 267, 278, 282, 284, 291, 308
 chimera (*see* chimera/chimeric)
 gene-targeting (*see* gene-targeted)
 model (*also see* animal model), 229,
 231, 234–235, 260
 transgenic (*see* transgene/transgenic)
M-phase specific phosphor-histone, 281
MSH2, 70
mucin-1 (MUC-1), 115, 119, 222, 225,
 227, 230, 231, 235, 303, 306
mucinous cystic neoplasm (MCN), 2–3,
 5–10, 72, 74, 91
multiplicity of infection (MOI), 264
multi-tissue tumor block (MTTB), 89
mung bean nuclease (*see* DNase)
mutagenesis, 276–277, 279, 282
mutation, 3, 74, 123–124, 143, 158,
 200, 208–209, 217–219, 221,
 224, 227, 229, 233, 245, 247,
 274, 276–277, 279–281, 305,
 320

N

N-cadherin, 275
neoplasia, 1–4, 68, 91, 217, 220–221,
 224, 228, 230, 234, 260
neoplasm, 2–10, 91, 67–68, 72, 74–75,
 199–200, 203, 217–221, 225,
 228–230, 260, 274

- NeuroD/Beta2*, 275, 279
 neuron-specific enolase (NSE), 72, 75
ngn3, 275
 nitrocellulose, 209–212, 215
nkx2.2, 275
nkx6.1, 275
 Notch signaling, 275
N-ras, 305
 nuclease
 endonuclease, 144, 146–148, 151–152, 156–157
 mung bean nuclease, 147, 149, 152, 156–157
 nuclease P1, 131
 ribonuclease H, 176
 S1 nuclease, 157
- O**
- oligonucleotide, 80, 123–124, 126, 129, 131, 138, 161, 175–176, 185, 200, 222, 250, 281, 284
 oncogene, 117, 143, 217, 225, 228, 231–232, 234–235, 274, 303, 305, 310, 320
 organogenesis (*see* pancreatic organogenesis)
 ortholog, 277, 279, 281
- P**
- p16*, 123–124, 218, 232, 234, 305
p48, 275
p53, 200, 208, 218, 221, 225, 232, 234, 303, 305
 pancreas/pancreatic
 adenoma (*see* adenoma)
 cancer, 1–7, 259–260, 273–274, 282, 329–331, 334, 336, 340
 classification, 1–7, 10, 331
 nomenclature, 1–2, 4, 10
 carcinoma, 1–7, 42, 68–70, 74, 127, 190–191, 199–201, 229–231, 235
 development, 259–260, 273–277, 279–282
 ductal adenocarcinoma (*also see* adenocarcinoma), 1–3, 68–70, 72, 74, 221, 224, 231, 259–260, 273–274
 ductal epithelial cells (*also see* ductal epithelial cells), 4, 113–114, 116–119, 225, 229, 231, 260
 isolate, 265, 267–268
 juice, 189, 191, 193, 195, 199–204
 organogenesis, 274, 276
 pancreas-specific transcription factor-1 (*PTF-1*), 275–276
 pancreatitis, 113, 175–176, 178, 186–187, 199–201, 260
 pancreatoblastoma, 72–73
 PanIN (pancreatic intraepithelial neoplasia), 1–5, 9–10, 68, 260
 paraffin (*also see* tissue embedding), 7, 9–10, 35–36, 41, 44–46, 55, 57–60, 75–79, 81, 89–90, 92–93, 95–99, 125–126, 128, 130, 134, 280, 287
pax 4, 275
pax 6, 275
 PCNA (proliferating cell nuclear antigen), 281
 PCR, 7–9, 38, 50–52, 54, 60, 79–80, 82–83, 137–141, 143, 147–149, 153–158, 162, 164–166, 169–170, 172–173, 179, 181, 183, 203, 246–247, 249–250
 methylation-specific (MSP), 124–134
 quantitative (*see* quantitative PCR)
PDX-1, 225, 231, 267–268, 275, 277, 279
 penetrance, 333–334, 336, 338
 peptide mapping, 189–196
 phenol-chloroform extraction, 38–40, 53–56, 62, 76, 80, 153, 165, 176–177, 179, 180, 187, 214, 283, 289

- phenol-enhanced reassociation technique (PERT), 145
- phenotype/phenotyping, 15–16, 20, 33, 59, 70, 116–117, 217–221, 228–229, 234–235, 259, 277, 330–332, 338–339
- PicoGreen, 140
- platelet-derived growth factor, 115
- polymorphism/polymorphic, 137–138, 151–152, 332
- precursor, 1–3, 7, 9–10, 72, 82, 113, 229, 259–260, 273, 276, 281, 301, 305
- primary tumor, 104, 107, 151, 221, 223
- proliferation/proliferative/proliferate, 3, 74–75, 103, 114–115, 143, 199, 221, 274, 276, 281
- protease, 60, 77, 193, 195, 199, 203
inhibitor 37, 44, 60–61, 63, 191, 199–200, 203
- proteinase K, 39, 52, 57–58, 76, 81, 83
- protein
analysis, 19, 50, 63, 68, 70, 73, 189–196, 203
identification, 189–196
isolation, 16, 19–20, 28, 35–37, 39, 41, 44, 47, 50, 57, 60–61, 190–196, 289
stability 35, 57, 59–60, 68, 77, 190
- proteomics, 189–191
- PTEN*, 144, 150
- p*-value, 330, 333, 335, 339
- Q**
- quality control, 15–63, 98, 186, 331–332
- quantitative PCR, 134, 138, 204
- R**
- rat, 114, 116, 217, 219–224, 260–262
- Rb*, 123–124, 228
- receiver-operating characteristic (ROC), 140
- recombinase-mediated cassette exchange (RMCE), 245, 250, 254–255
- recombinase-mediated DNA insertion (RMDI), 245, 253–254
- representation differential analysis (RDA), 125–127, 129, 132–134, 143–158
- restriction enzyme digestion (*also see* DNA digestion), 126–127, 129, 131–132, 162, 250, 289
- restriction landmark genome scanning (RLGS), 125, 127, 133
- retrovirus (*see* virus)
- riboprobe, 79–81, 83, 289–290
- risk, 18, 28, 44, 47, 60, 211, 217, 219, 228, 260, 267, 273, 329–331, 333, 335, 338–340
- RNA
analysis, 50, 58, 59, 63
cRNA, 133, 177, 180–181, 183
isolation, 9, 19–21, 35–36, 40–41, 44, 47, 54–56, 60–61, 63, 133, 166, 176, 178–179, 209–210, 214
mRNA, 89, 162, 164, 166, 178, 185, 189–190, 200, 209–210, 215
polymerase, 179–180, 283, 289
precipitation, 289
probe (*also see* riboprobe), 79–80, 288
quality, 57, 59–60, 63, 83, 166, 172–173, 214
quantity, 60–61, 63, 81, 173, 180, 189–190, 210
sense/antisense, 288, 292
tRNA, 284
total RNA, 41, 54, 56, 63, 133, 166, 172–173, 176, 178–179, 210, 215
- RNase, 18, 40, 45, 52, 54–55, 60, 76, 79, 81–82, 177, 180, 199, 203, 283, 289, 293

inhibitor, 37, 41, 54, 56, 60, 76, 81,
180, 199
RPA, 115

S

secretin, 115–116, 199, 201, 203
segregation analysis, 333–334, 338
selenium, 115
senescence, 117
SEREX (serological analysis of
recombinant tumor cDNA
expression libraries), 207–210,
213, 215
serial analysis of gene expression
(SAGE), 161–173
serous cystadenoma, 72, 234
serum, 33, 40, 77, 106, 117–118, 128,
130, 153, 167, 177, 189, 191,
207–215, 261, 269, 273,
282–284, 290
sequencing, 132, 134, 139, 161–173,
209, 214, 276
sequential probability ratio test (SPRT),
140
single nucleotide polymorphism (SNP),
137–141
site-specific recombinase, 245–247,
250, 254
SMAD4 (*also see DPC4*), 9–10, 234–235
solid-pseudopapillary neoplasm, 74
somatostatin, 72, 115, 277–279
sonic hedgehog (*shh*) 275, 277
statistic, 330, 333, 335–337, 339
stem cell, 116, 231
STK11, 329–330
stroma/stromal, 3, 5, 8–9, 51, 59, 62, 69–70,
72, 80, 103, 111, 175–176, 178,
186–187, 220, 223, 229
desmoplasia, 70
subtractive hybridization, 127, 143,
147, 149–151, 155, 161
sucrose infusion, 35, 43

surface-enhanced laser desorption
ionization (SELDI), 189–191,
193–196
SV40, 117, 224

T

tag/ditag, 162–173
tagging enzyme, 162, 168
T-cells, 103, 208, 219, 222, 300–308, 312
telomerase, 117, 199–204
telomerase amplification protocol
(TRAP), 200–201, 203
TGF α , 224–225, 228, 234–235, 260
TGF β , 275
tissue, 274–277, 280
antigen, 59, 77, 286
collection, 15, 19, 32, 47–48, 50, 92–
95, 178
culture, 113–119, 259–269
disaggregation, 33, 42
embedding (*also see* paraffin), 7, 9,
36, 44, 75–77, 79, 89, 125
fixation, 7, 34–36, 43, 77, 79, 109
freezing/frozen, 9, 20–21, 32, 36, 41,
44, 77, 125, 210
microarray (TMA)/array, 10, 82, 89–100
permeability, 286, 288
processing, 15–63
resolution, 280, 287
scrapping, 7, 9, 33, 42
sectioning (*also see* frozen section), 7,
10, 36, 44, 89, 93, 96–97, 187
-specific, 226–228, 230, 234, 245
staining (*also see* staining,
immunohistochemistry), 7,
9–10, 19–20, 36–37, 44–46,
93, 187
storage, 15, 60, 99
transdifferentiation, 260, 274
transferring, 115
transgene/transgenic (*also see* inducible
transgene), 217–219, 224,
228–231, 234–235, 256

TRIZol, 38, 133, 164, 166, 173, 176, 178–179
 trypsin, 70, 74, 104, 106, 115–118, 193, 195–196, 264, 279
 inhibitor 115, 118, 261–262, 269
 tumor
 antigen, 207–208, 302–308, 312
 development, 10, 68–75, 217–236
 genome, 143–144, 150–152
 immunology, 207–215, 299–320
 marker, 190, 259–260, 273–274
 samples, 151–152, 178–179
 tumorigenesis, 114, 274
 tumor necrosis factor α (*TNF- α*), 319
 tumor-suppressor gene, 68, 123–124, 126, 143–144, 150, 217, 232–235, 274, 305
 two-dimensional polyacrylamide gel electrophoreses (2D-PAGE), 189–191, 193–196

V

vaccine, 207, 299–300, 304–310, 312, 318–320
 vector (*also see* viral/virus), 119, 132, 162, 210, 214, 227, 232, 246–247, 250, 253, 256, 289, 309–313, 315–320
 VEGF, 222–223
 ventral, 265, 267, 275
VHL, 123–124
 vimentin, 115–116
 viral/virus
 adenovirus, 261, 264, 267–268
 antiviral assay, 319
 DNA, 311
 Epstein-Barr, 70

Herpes simplex virus (HSV), 232, 247, 250, 254
 human papillomavirus (HPV), 117–118
 infection, 310
 Moloney murine leukemia virus (Mo-MuLV), 311
 oncogene, 117, 225
 particle, 311, 314–315
 producer, 312–313, 315–316
 protein, 311
 recombinant, 314
 retrovirus, 119, 309–318
 RNA, 70, 311
 vector, 119, 309–313, 315–320

W

whole cell vaccine, 299–300
 whole-mount, 280–282, 286–287, 292
 workflow management, 15, 21

X

X-chromosome inactivation, 124
 xenogeneic, 217, 219
 xenograft, 103–111, 151–152

Y

yeast artificial chromosome (YAC), 144

Z

zebrafish, 273–293
 zymogen, 263, 277